We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Serum Protein Biomarkers Detect Invasive Breast Cancer

By LabMedica International staff writers
Posted on 01 Oct 2014
The ability of serum protein biomarkers in conjunction with autoantibodies to distinguish between invasive breast cancer and benign breast conditions has been demonstrated.

It has been estimated that 233,000 women will be diagnosed with breast cancer in the USA in 2014 and approximately 40,000 deaths occur from breast cancer each year. More...
While biomarkers are often used to augment detection of various cancers, definitive biomarkers for breast cancer have remained elusive.

Data is now available from a study that measured serum protein biomarkers (SPBs) known to be associated with breast cancer in over 163 serum samples from women with either breast cancer or benign breast conditions. In addition, 28 autoantibodies (AAbs) associated with cancer were analyzed in 31 of these patients. The study demonstrated that the addition of AAbs to a panel of SPBs greatly increases accuracy and using SPBs to distinguish benign from invasive breast cancer yields reasonable but non-clinically meaningful results in menopausal women.

Provista Diagnostics, Inc., (Scottsdale, AZ, USA) is a privately-held molecular diagnostics company focused on developing and commercializing proprietary blood-based diagnostic, prognostic and monitoring tests for cancers affecting women, that announced the data highlighting Provista's proteomic diagnostic that measures multiple breast cancer-specific biomarker proteins in blood samples.

David Reese, PhD, president and CEO of Provista, said, “The presentation of this proof-of-concept data is a major milestone for Provista as we continue to advance the development of our robust pipeline to detect breast and gynecologic cancers in women. Accurate clinical diagnosis of breast cancer depends on the effective use of complementary technologies in conjunction with standard of care, such as imaging. We believe our proteomics approach, which combines the sensitivity of autoantibodies with the specificity of known serum protein biomarkers along with standard-of-care imaging, may reduce the number of missed actionable breast cancers while avoiding the stress and added diagnostic costs of false negative reports.” The study was presented at The American Society of Clinical Oncology's 2014 Breast Cancer Symposium (ASCO-Breast 2014) that took place from September 4-6, 2014, in San Francisco (CA, USA).

Related Links:
Provista Diagnostics


New
Gold Member
Automatic CLIA Analyzer
Shine i9000
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Collection and Transport System
PurSafe Plus®
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: Residual leukemia cells may predict long-term survival in acute myeloid leukemia (Photo courtesy of Shutterstock)

MRD Tests Could Predict Survival in Leukemia Patients

Acute myeloid leukemia is an aggressive blood cancer that disrupts normal blood cell production and often relapses even after intensive treatment. Clinicians currently lack early, reliable markers to predict... Read more

Immunology

view channel
Image: The simple blood marker can predict which lymphoma patients will benefit most from CAR T-cell therapy (Photo courtesy of Shutterstock)

Routine Blood Test Can Predict Who Benefits Most from CAR T-Cell Therapy

CAR T-cell therapy has transformed treatment for patients with relapsed or treatment-resistant non-Hodgkin lymphoma, but many patients eventually relapse despite an initial response. Clinicians currently... Read more

Pathology

view channel
Image: Determining EG spiked into medicinal syrups: Zoomed-in images of the pads on the strips are shown. The red boxes show where the blue color on the pad could be seen when visually observed (Arman, B.Y., Legge, I., Walsby-Tickle, J. et al. https://doi.org/10.1038/s41598-025-26670-1)

Rapid Low-Cost Tests Can Prevent Child Deaths from Contaminated Medicinal Syrups

Medicinal syrups contaminated with toxic chemicals have caused the deaths of hundreds of children worldwide, exposing a critical gap in how these products are tested before reaching patients.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.